News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

University of Pennsylvania Researchers Use Cellulose to Produce Accurate Rapid COVID-19 Test Results Faster and Cheaper than Traditional PCR Tests

Researchers are working to create accurate rapid COVID-19 tests with lower costs and less waste than existing rapid clinical laboratory tests

University of Pennsylvania (UPenn) researchers have developed a biodegradable rapid COVID-19 test that raises the bar on traditional polymerase chain reaction (PCR) tests, which throughout the COVID-19 pandemic have been the gold standard for SARS-CoV-2 diagnostic testing.

Many clinical laboratory professionals are aware of the significant amount of waste going into landfills from spent COVID-19 rapid PCR tests that use biosensors to produce results. These biosensor systems “use printed circuit boards, or PCBs, the same materials used in computers. PCBs are difficult to recycle and slow to biodegrade, using large amounts of metal, plastic, and non-eco-friendly materials,” according to a Penn Engineering Today blog post.

UPenn’s new test does not use PCBs. Instead, its biosensor uses “bacterial cellulose (BC), an organic compound synthesized from several strains of bacteria,” the blog post noted.

“This new BC test is non-toxic, naturally biodegradable and both inexpensive and scalable to mass production, currently costing less than $4.00 per test to produce. Its cellulose fibers do not require the chemicals used to manufacture paper, and the test is almost entirely biodegradable,” the blog post continued.

The Penn engineers published their findings in the journal Cell Reports Physical Science titled, “A Bacterial Cellulose-Based and Low-Cost Electrochemical Biosensor for Ultrasensitive Detection of SARS-CoV-2.”

Cesar de la Fuente, PhD

“There is a need for biodegradable diagnostic testing,” said Cesar de la Fuente, PhD (above), Presidential Assistant Professor in the Psychiatry Department at the University of Pennsylvania’s Perelman School of Medicine. “We will be continuing to perfect this technology, which could hopefully help many people in the future, while also looking to expand it to other emerging pathogens in anticipation of future pandemics.” Clinical laboratories engaged in SARS-CoV-2 testing during the COVID-19 pandemic can attest to the massive amounts of waste generated by traditional PCR testing. (Photo copyright: University of Pennsylvania.)

Evolution of Improvement for SARS-CoV-2 Diagnostic Assays

Cesar de la Fuente, PhD, is Presidential Assistant Professor in the Psychiatry Department at the Perelman School of Medicine. His lab has been hard at work since the start of the pandemic to improve COVID-19 testing. The recent study was a collaboration between University of Pennsylvania’s de la Fuente Lab and William Reis de Araujo, Professor in Analytical Chemistry at the State University of Campinas (UNICAMP) in São Paulo, Brazil.

De Araujo leads the Portable Chemical Sensors Lab and has been pairing his electrochemistry expertise with de la Fuente’s lab for years, Penn Engineering Today noted.

The team wanted to combine the speed and cost-effectiveness of previous rapid tests with an eco-friendly biodegradable substrate material.

Bacterial cellulose (BC) was a great choice because it “naturally serves as a factory for the production of cellulose, a paper-like substance which can be used as the basis for biosensors,” Penn Engineering Today reported.

Additionally, BC has an excellent track record for a variety of uses, such as regenerative medicine, wound care, and point-of-care (POC) diagnostics, the blog post noted. UPenn’s test offers speed and accuracy without needing costly equipment making it desirable for clinical laboratories preparing to fight the next pandemic.

The test has shown to be capable of “correctly identifying multiple variants in under 10 minutes. This means that the tests won’t require ‘recalibration’ to accurately test for new variants,” Penn Engineering Today added.

Innovation Born from Inspiration

Though rapid tests are essential to help curb the spread of COVID-19, the negatives that come with these tests didn’t sit well with the UPenn team. This spurred them to strive for improvements.

PCR tests “are hampered by waste [metal, plastic, and the aforementioned PCBs]. They require significant time [results can take up to a day or more] as well as specialized equipment and labor, all of which increase costs,” Penn Engineering Today noted.

Additionally, “Sophistication of PCR tests makes them harder to tweak and therefore slower to respond to new variants,” the blog post concluded.

“There’s a tension between these two worlds of innovation and conservation,” de la Fuente told Penn Engineering Today. “When we create new technology, we have a responsibility to think through the consequences for the planet and to find ways to mitigate the environmental impact.” 

Need for Biodegradable Diagnostic Tests

“COVID-19 has led to over 6.8 million deaths worldwide and continues to affect millions of people, primarily in low-income countries and communities with low vaccination coverage,” the Cell Reports Physical Science paper noted.

“There is a need for biodegradable diagnostic testing,” de la Fuentes told Penn Engineering Today. “We will be continuing to perfect this technology, which could hopefully help many people in the future, while also looking to expand it to other emerging pathogens in anticipation of future pandemics.”

While UPenn’s test will require clinical trials and FDA approval before it can become available to clinical laboratories and for point-of-care testing, it promises a bright, eco-friendly future for rapid viral testing.

—Kristin Althea O’Connor

Related Information:

Penn Engineers Create Low-Cost, Eco-Friendly COVID Test

A Bacterial Cellulose-Based and Low-Cost Electrochemical Biosensor for Ultrasensitive Detection of SARS-CoV-2

Rapid COVID-19 Diagnostic Test Delivers Results within Four Minutes with 90% Accuracy

Penn Researchers Develop Faster, Biodegradable COVID-19 Tests

Penn Medicine Researchers Develop Fast, Accurate, Inexpensive COVID-19 Diagnostic Test Based on Electrochemical Technology

15-Minute Diagnostic Biomarkers for Cancer, Other Conditions Unveiled in UK

Use of antibodies that detect biomarkers in as little as 15 minutes now allows researchers at the University of Leeds in the United Kingdom to identify such diseases as prostate and ovarian cancer, stroke, multiple sclerosis (MS), heart disease, and fungal infections. Using biosensors to identify the molecular markers for disease, the technology is much faster than current testing methods.

One goal of this research is to provide a way for hospitals to use this technology for rapid diagnosis. Another goal is to allow surgeons to use the technology to improve the speed and accuracy of referral to specialty physicians. Along with the ability to identify cancer, MS, heart disease, and infections, researchers say these biosensors may also be able to detect a wide range of analytes, including biomarkers in tuberculosis and HIV.
“We believe this to be the next generation diagnostic testing. We can now detect almost any analyte faster, cheaper, and more easily than the current accepted testing methodology,” said Paul Millner, M.D, a member of the faculty of Biological Sciences at the University of Leeds.

Researchers say that this technology could be developed into a device the size of a mobile phone, where different sensor chips could be inserted, depending on the disease being sought. “We’ve designed simple instrumentation to make the biosensors easy to use and understand,” Millner explained. “They’ll work in a format similar to the glucose biosensor testing kits that diabetics use.”

Currently blood and urine are tested for disease markers using test technologies such as ELISA (enzyme-linked immunosorbant assay). Developed in the 1970s, ELISA takes an average of two hours to complete, can be expensive, and can be performed only by highly trained staff.

The new biomarker technology was developed through a European collaboration of researchers and commercial partners in a 2.7 million Euro ($3.6 million) project called ELISHA (Electronic Immuno-Interfaces and Surface Nanobiotechnology: A Heterodoxical Approach).

Related Information

;